Silvia Calabria

Ms. Silvia Calabria

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2019 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
CPCarlo Piccinni
Carlo Piccinni
SCSabina Cevoli
Sabina Cevoli
GRGiulia Ronconi
Giulia Ronconi
LDLetizia Dondi
Letizia Dondi
SCSilvia Calabria
Silvia Calabria
NMNello Martini
Nello Martini
Although migraine is a disabling neurological condition that causes important disability, it remains an area of underdiagnosis and undertreatment worldwide. The aim of this study was to depict the burden of the unmet medical needs in migraine treated with triptans in a large Italian population. A 2-year longitudinal analysis of migraineurs with unmet medical needs on treatment with triptans was performed. The studied cohort consisted of subjects with ≥4 triptan dose units per month, selected from the general population These patients were stratified into: possible Low-Frequency Episodic Migraine (pLF-EM: 4–9 triptan dose units per month), possible High-Frequency Episodic Migraine (pHF-EM: 10–14 triptan dose units per month) and possible Chronic Migraine (pCM:> 14 triptan dose units per month). The first follow-up year was analysed to describe the use of preventive therapies, the second year to describe the ≥50% reduction in triptan use. Of 10,270,683 adults, 8.0 per 1000 were triptan users and, of these, 38.2% were migraineurs with unmet medical needs, corresponding to 3.1 per 1000 adults. By stratifying for the number of triptan dose units per month, 72.3% were affected by pLF-EM, 17.4% by pHF-EM, and 10.3% by pCM. In this cohort, 19.1% of individuals used oral preventive drugs and 0.1% botulinum toxin. Triptan use reduction was found in 22.3% individuals of the cohort, decreasing with the intensification of need levels (25.8% pLF-EM, 13.6% pHF-EM, 12.0% pCM). This real-life analysis underlined that the unmet medical needs concern a large part of patients treated with triptans and there is an undertreatment with preventive therapies whose benefit is insufficient, which may be due to the lack of effective preventive strategies, probably still reserved to severe patients. This study allows forecasting the actual impact of newest therapeutic strategies aimed to fill this gap.

1 November 2017 in International Journal of Cardiology
Verified
Journal Article
Closed access
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
SCSilvia Calabria
Silvia Calabria
ERElisa Rossi
Elisa Rossi
NMNello Martini
Nello Martini

1 April 2016 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
SCSilvia Calabria
Silvia Calabria
ECElisa Cinconze
Elisa Cinconze
MRMaurizio Rossini
Maurizio Rossini
ERElisa Rossi
Elisa Rossi
Aldo Pietro MaggioniAldo Pietro Maggioni
Aldo Pietro Maggioni
MRMarisa De Rosa
Marisa De Rosa
Purpose: Osteoporosis is a chronic disease and an important health and social burden due to its worldwide prevalence. Literature and clinical experience report incomplete adherence to the therapy. This retrospective observational study aimed at assessing the adherence to first-line antiosteoporosis drugs (AODs; reimbursed by the National Health System, according to the Italian Medicine Agency recommendation number 79), alendronate or risedronate, with or without calcium and/or vitamin D supplements, in a real, Italian clinical setting. Patients and methods: Analyses were carried out on data present in the ARNO Observatory, a population-based patient-centric Italian database. From a population of 5,808,832 inhabitants with available data, a cohort of 3.3 million of patients aged ≥40 years was selected. New users of first-line AODs as monotherapy (accrual period, 2007–2009) were followed up over 3 years to assess adherence at 6, 12, and 36 months to AODs and to supplements and related determinants. Results: Approximately 40,000 new users were identified: mostly women, aged on average (standard deviation) 71±10 years. Alendronate was the most prescribed (38.2% of patients), followed by risedronate (34.9%) and alendronate with colecalciferol as a fixed-dose combination (25.8%). Adherence at the 6-month follow-up was 54%, and this constantly and significantly decreased after 1 year to 46%, and after 3 years to 33% (P50 years were more likely to adhere to treatment regimen (P5 drugs), cardiovascular, and neurological therapies were significantly associated with low adherence throughout the follow-up period. Conclusion: In a huge clinical practice sample, this study highlights suboptimal adherence to first-line AODs and to supplements and important determinants, such as concomitant therapies.

18 February 2024 in European Journal of Internal Medicine
Verified
Journal Article
Open access
GCGiacomo Cafaro
Giacomo Cafaro
CPCarlo Perricone
Carlo Perricone
GRGiulia Ronconi
Giulia Ronconi
SCSilvia Calabria
Silvia Calabria
LDLetizia Dondi
Letizia Dondi
NMNello Martini
Nello Martini
Objectives: Primary Sjogren's syndrome (pSS) is a systemic autoimmune disease with significant impact on morbidity, mortality, and quality of life. This study aimed to evaluate epidemiology, healthcare needs and related costs of pSS patients from the Italian National Health Service perspective. Methods: From the Fondazione Ricerca e Salute's database (similar to 5 million inhabitants/year), pSS prevalence in 2018 was calculated. Demographics, mean healthcare consumptions and direct costs at one year following index date (first in-hospital diagnosis/disease waiver claim) were analysed through an individual direct matched pair casecontrol analysis (age, sex, residency). Results: In Italy, 3.8/10,000 inhabitants were identified as affected by pSS (1,746 case: 1,746 controls) in 2018. In the year following index date, 53.7% of cases and 42.7% of controls received >= 1 drug (p<0.001); mean per capita cost was 501 and 161, respectively (p<0.01). At least one hospitalization occurred to 7.8% of cases and 3.9% of controls (p<0.001) with mean per capita costs of 416 and 129, respectively (p = 0.46). At least one outpatient specialist service was performed in 49.8% of cases and 30.6% of controls (p<0.001); mean per capita costs were 200 and 75, respectively (p<0.01). Overall, mean annual costs were 1,171 per case and 372 per control (p < 0.01). Conclusion: According to results of this population-based study, the prevalence of pSS in Italy appears to be consistent with the definition of rare disease. Patients with pSS have higher pharmacological, in-hospital and outpatient specialist care needs, leading to three-times higher overall cost for the INHS, compared to the general population.

1 April 2020 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SCSilvia Calabria
Silvia Calabria
GRGiulia Ronconi
Giulia Ronconi
LDLetizia Dondi
Letizia Dondi
CPCarlo Piccinni
Carlo Piccinni
APAntonella Pedrini
Antonella Pedrini
NMNello Martini
Nello Martini

25 May 2021 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
GRGiulia Ronconi
Giulia Ronconi
LDLetizia Dondi
Letizia Dondi
SCSilvia Calabria
Silvia Calabria
CPCarlo Piccinni
Carlo Piccinni
APAntonella Pedrini
Antonella Pedrini
NMNello Martini
Nello Martini